Otsuka Holdings said this week it plans to move renal denervation assets it acquired commercialization rights it acquired last year to its wholly-owned subsidiary, Otsuka Medical Devices.
Otsuka said that its board of directors has voted to move the business to its subsidiary Otsuka Medical Devices in an attempt to “optimize the allocation of group resources” to “further strengthen the group’s business platform,” according to a press release.
The simplified company split will become effective on January 1, 2018, and includes the issuance of 80,000 shares of common stock to Otsuka Holdings.
Otsuka said that the split is expected to have “only minor impacts on the consolidated business results” since the move is to a wholly owned subsidiary.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.